Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis

Yun Hee Lee; Yeon Sil Kim; Sang Nam Lee; Hyo Chun Lee; Se Jin Oh; Seoung Joon Kim; Young Kyoon Kim; Dae Hee Han; Ie Ryung Yoo; Jin Hyung Kang; Suk Hee Hong

doi:10.4143/crt.2014.180

Articles

Page Path: HOME > Cancer Res Treat > Volume 47(4); 2015 > Article

Original Article Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis: Yun Hee Lee, MD¹, Yeon Sil Kim, MD¹, Sang Nam Lee, MD¹, Hyo Chun Lee, MD¹, Se Jin Oh, MD¹, Seoung Joon Kim, MD², Young Kyoon Kim, MD², Dae Hee Han, MD³, Ie Ryung Yoo, MD⁴, Jin Hyung Kang, MD⁵, Suk Hee Hong, MD⁵; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2015;47(4):676-686.
DOI: https://doi.org/10.4143/crt.2014.180
Published online: February 13, 2015

¹Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

³Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁴Department of Nuclear Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁵Department of Medical Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence: Yeon Sil Kim, MD Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea
Tel: 82-2-2258-6259 Fax: 82-2-592-1532 E-mail: yeonkim7@catholic.ac.kr

• Received: July 11, 2014 • Accepted: September 13, 2014

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

16,850 Views
208 Download
57 Web of Science
52 Crossref
64 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
We examined clinical and dosimetric factors as predictors of symptomatic radiation pneumonitis (RP) in lung cancer patients and evaluated the relationship between interstitial lung changes in the pre-radiotherapy (RT) computed tomography (CT) and symptomatic RP.
Materials and Methods
Medical records and dose volume histogram data of 60 lung cancer patients from August 2005 to July 2006 were analyzed. All patients were treated with three dimensional (3D) conformal RT of median 56.9 Gy. We assessed the association of symptomatic RP with clinical and dosimetric factors.
Results
With a median follow-up of 15.5 months (range, 6.1 to 40.9 months), Radiation Therapy Oncology Group grade ≥ 2 RP was observed in 14 patients (23.3%). Five patients (8.3%) died from RP. The interstitial changes in the pre-RT chest CT, mean lung dose (MLD), and V₃₀ significantly predicted RP in multivariable analysis (p=0.009, p < 0.001, and p < 0.001, respectively). MLD, V₂₀, V₃₀, and normal tissue complication probability normal tissue complication probability (NTCP) were associated with the RP grade but less so for grade 5 RP. The risk of RP grade ≥ 2, ≥ 3, or ≥ 4 was higher in the patients with interstitial lung change (grade 2, 15.6% to 46.7%, p=0.03; grade 3, 4.4% to 40%, p=0.002; grade 4, 4.4% to 33.3%, p=0.008). Four of the grade 5 RP patients had diffuse interstitial change in pre-RT CT and received chemoradiotherapy.
Conclusion
Our study identified diffuse interstitial disease as a significant clinical risk for RP, particularly fatal RP. We showed the usefulness of MLD, V₂₀, V₃₀, and NTCP in predicting the incidence and severity of RP.
Key words: Radiation pneumonitis, Interstitial lung diseases, Lung neoplasms, Radiotherapy

Introduction

Thoracic radiation therapy (RT) is an important component of treatment for locally advanced non-small cell lung cancer and limited stage small cell lung cancer [1-4]. The fundamental goal of RT is to deliver an effective dose for local control and keep toxicity to an acceptable level in the surrounding normal tissues. However, irradiation of the thorax is frequently accompanied by harmful side effects. One major concern is radiation pneumonitis (RP), which can lead to severe respiratory dysfunction, including chronic respiratory insufficiency caused by the development of pulmonary fibrosis, and even death [5,6].

Clinical risk factors for the development of RP include older age, disease location in the mid-lower lung, chemotherapy-schedule, and the presence of comorbidity [7,8]. Additionally, many studies suggest dosimetric factors relate to RP [9-12].

Several studies reported that patients with interstitial lung disease (ILD) developed severe RP after thoracic stereotactic body radiotherapy (SBRT) [13,14]. Acute exacerbation of ILD can cause respiratory failure and death. Severe ILD was regarded as a relative contraindication in the clinical guidelines for SBRT published by the Japanese Society for Therapeutic Radiation and Oncology [15]. There is limited data showing an association of subclinical ILD with RP [16,17], and whether subclinical ILD is a risk factor for thoracic RT is a matter of speculation.

We examined clinical and dosimetric factors as predictors of symptomatic RP in lung cancer patients and further evaluated the relationship of pre-radiation interstitial changes in the computed tomography (CT) and symptomatic RP.

Materials and Methods

1. Patients

The medical records and dose volume histogram (DVH) data of 60 lung cancer patients, treated with three dimensional (3D) conformal RT from August 2005 to July 2006 at Seoul St. Mary's Hospital, were retrospectively collected and analyzed. At least 6 months of follow-up was required for inclusion in this study. Patients who died within 6 months after completion of RT, were lost to follow-up, or did not complete treatment, were excluded from the analysis.

Patient characteristics are summarized in Table 1. All 60 patients were treated with curative intent, using 3D conformal RT. Forty-eight patients (80%) received chemotherapy as a part of their definitive treatment. Twenty-seven patients (45%) received chemotherapy prior to RT and 21 patients (35%) received concurrent chemoradiotherapy. The regimens used for concurrent chemotherapy were etoposide and cisplatin (8 patients), docetaxel and cisplatin (8 patients), taxol (4 patients), and cisplatin (1 patient). Fourteen patients (23.3%) received RT or concurrent chemoradiotherapy as definitive salvage treatment following recurrent disease after surgical intervention (lobectomy eight patients, wedge resection two patients, pneumonectomy one patient, and others three patients). Fifty-two patients (86.7%) showed a good performance status of more than Eastern Cooperative Oncology Group (ECOG) 2. Each patient’s pre-RT chest CT scans were reviewed by two radiation oncologists and one diagnostic radiologist who were not informed of which patients developed symptomatic RP. Fifteen patients (25%) had interstitial changes on their chest CT scans. Interstitial changes were recorded if any of the following criteria were met: subpleural ground glass opacity (GGO), fibrous reticulation, traction bronchiectasis, micronodules, honey-comb appearance, or volume loss, especially in both lower lobes [18]. Thoracic RT was not performed in patients with clinical ILD, which was defined as a status of symptomatic disease or post-treatment with high probability of acute exacerbation. The patients showing interstitial change on pre-RT CT without related symptom or history of a treatment were included in this study as subclinical ILD. This retrospective study was approved by the hospital’s institutional review board.

2. Radiation therapy

A planning CT scan with contrast enhancement of the entire lung volume was acquired with a vac-lock immobilization device at shallow normal breathing. Four dimensional CT (4D-CT) scans were also acquired in all patients to evaluate respiratory motion. All patients underwent virtual simulation and treatment planning with the 3D treatment planning system (Pinnacle, ADAC Laboratories, Milpitas, CA). The calculation was performed with lung heterogeneity corrections by radiological path algorithm. The gross tumor volume (GTV) included the tumor and the clinically involved nodes. The GTV node was determined by chest CT and/or positron emission tomography–computed tomography for the majority of patients; the node was determined by mediastinoscopy in a small number of patients. The clinical target volume included the GTV with an additional uniform 5-mm expansion and high risk, uninvolved mediastinal lymph nodes as well as the ipsilateral hilar lymph nodes. The high risk, involved mediastinal lymph nodes were defined as those lymph nodes adjacent to the GTV node with a high probability of microscopic involvement. We added a different panning target volume (PTV) margin based on an assessment of each tumor’s motion using the Leonardo system (Siemens, Concord, CA) in 4D-CT. The lung, esophagus, spinal cord, and heart were contoured. The lung volume was contoured and defined excluding the GTV.

Most patients were treated with conventional beam arrangements (i.e., initial AP/PA fields to include the PTV) for the first 30-40 Gy, followed by an off-cord oblique beam to the PTV, usually composed of three to five beams. Some patients with small PTVs were treated with multiple beam arrangements from the beginning. The median radiation dose was 56.9 Gy (range, 45.0 to 64.8 Gy), generally delivered at 1.8-2 Gy/fraction, five fractions per week. RT was delivered with 10 MV X-ray from a LINAC (Siemens). Generally, the radiation dose was prescribed such that 95% of PTV was covered by 95% of the prescription dose. The lung DVH was calculated directly from the physical dose distribution (i.e., adjustments were not made for fraction size or overall treatment time). The following dosimetric factors were extracted from the lung DVH: V₁₀, V₂₀, V₃₀, V₄₀, mean lung dose (MLD), and normal tissue complication probability (NTCP) as derived from the Lyman and Kutcher models.

3. Evaluation of RP

A diagnosis of RP was made by the clinical symptoms of nonproductive cough, fever, exertional dyspnea and characteristic chest radiographs and CT findings. Patients were evaluated by radiation oncologists 3 to 6 weeks after completion of RT and at 1- to 3-month intervals thereafter. RP grading was recorded using Radiation Therapy Oncology Group (RTOG) scale, based on the severity of clinical symptoms and radiographic changes. Two radiation oncologists and one diagnostic radiologist who were blinded to RP status reviewed the medical records, chest X-ray and/or chest CT scan of all patients with suspected RP, and ruled out other causes of pneumonia that were confirmed as infectious pneumonia or disease progression.

4. Statistical analysis

All statistical analysis in this study was performed with the SPSS ver. 18.0 (SPSS Inc., Chicago, IL). The chi-squared test and Fisher exact test were used to compare RP risk in subgroups and Student’s t test was used for normally distributed continuous variables. To identify independent predictors of RP, all factors were included in a multivariable linear regression model. Using a stepwise procedure, variables with a p-value of 0.05 or higher were dropped from the model so that only significant predictors remained. All statistical tests were two sided and a p-value of less than 0.05 was considered statistically significant.

Results

1. RP incidence

With a median follow-up of 15.5 months (range, 6.1 to 40.9 months), 22 patients (36.7%) developed RP: eight (13.3%) with grade 1, six (10.0%) with grade 2, one (1.6%) with grade 3, 2 (3.3%) with grade 4, and five (8.3%) with grade 5. RTOG grade 2 or higher RP was observed in 14 patients (23.3%). Five patients (8.3%) died from RP. The median time to the onset of symptoms was 33 days (range, 6 to 160 days) from the completion of RT.

2. Clinical and dosimetric factors

Table 2 shows the relationship between clinical factors and RP. There was a trend of increased risk of RP in patients treated with combined chemoradiation compared with patients treated with RT alone (41.7% vs. 16.7%, p=0.108). However, this difference was not statistically significant. Interstitial change in the pre-RT chest CT was the only clinical factor associated with RP (p=0.033). In multivariable analysis, interstitial changes in the pre-RT chest CT were significantly associated with RP (p=0.009; odds ratio, 10.24; 95% confidence interval, 1.787 to 58.679).

The statistically significant dosimetric factors for predicting RP are shown in Table 3. In the univariable analysis, the radiation field size, MLD, V₁₀, V₂₀, V₃₀, V₄₀, and NTCP were significantly associated with RP (all p < 0.05). From the multivariable analysis, the MLD (p < 0.001) and V₃₀ (p < 0.001 were significant independent predictors for RP. Cumulative curves of the development of RP stratified by MLD, V₂₀, V₃₀, and NTCP are illustrated in Fig. 1. Our data showed that maintaining an MLD less than 15 Gy, V₂₀ ≤ 25 %, and V₃₀ ≤ 20 % could reduce the incidence of RP. Fig. 2 illustrates the distribution of RP grades by MLD, V₂₀, V₃₀, and NTCP. As shown in Fig. 2, five patients with grade 5 RP did not have higher dosimetric parameters compared to non-fatal RP patients.

3. Interstitial change in pre-RT CT

Fifteen patients (25%) had interstitial changes on their chest CT scans. There was a difference in RP incidence between patients with interstitial lung change in pre-RT CT and without interstitial change (Table 4). RP was detected in nine (60.0%) of the 15 patients with diffuse interstitial change in their pre-RT CT compared to 13 (28.9%) of 45 patients without interstitial changes (p=0.030). Risk of RP grade ≥ 2 was significantly different depending on presence of interstitial change in the patient’s pre-RT CT (p=0.030). In addition, interstitial change in pre-RT CT raised the risk of RP grade ≥ 3 and ≥ 4 from 4.4% to 40% (p=0.002) and 4.4% to 33.3% (p=0.008). Interstitial change in pre-RT chest CT was the only clinical factor associated with RP in the multivariable analysis (p=0.009).

We analyzed the pre-RT chest CT of the RP patients, by focusing on the imaging findings. Of these patients, the characteristic findings of the nine RP patients with diffuse interstitial changes in their pre-RT chest CT scans are summarized in Table 5. These patients presented mixed and various interstitial changes such as honeycombing, reticular opacity, traction brochiectasis, focal subpleural GGO, and micronodular density. However, in the higher grade RP patients, diffuse honeycombing and diffuse nodular density patterns were frequently observed involving the entirety of both lungs diffusely, or occasionally involving both lower lung fields. Fig. 3 shows a typical representative case of a patient who progressed to fatal RP. Four of the grade 5 RP patients had interstitial changes in their pre-RT chest CT and also received chemotherapy: concurrent chemoradiotherapy in two patients, and sequential chemotherapy followed by RT in two patients.

Table 6 gives a detailed description of five patients with grade 5 RP. Three patients initially developed focal consolidation corresponding to the radiation fields during RT or within one month after RT completion, and the lesions progressed to the entire lung beyond radiation fields. The other two patients presented with bilateral lung infiltration 4 to 6 weeks after RT completion and died following rapid progression. No pathogens were identified and steroid and antibiotic treatments were not effective.

Discussion

In this study, we examined clinical and dosimetric factors as predictors of symptomatic RP in lung cancer patients and further evaluated the relationship of pre-radiation interstitial changes in the CT with symptomatic RP, as there are limited data for interstitial change in pre-RT CT regarding RP. The RP risk differed significantly by the presence of interstitial lung change in the pre-RT CT. The risk of RP grade ≥ 2 or ≥ 3 was elevated in patients with interstitial change in their pre-RT CT scans. Interstitial change in the pre-RT chest CT scan was the only clinical factor associated with RP in the multivariable analysis.

Patient performance status, age, sex, smoking status, chemotherapy exposure, tumor site, and pre-RT pulmonary function test have been implicated in RP [7,8]. Several studies [12,19] showed that the chemotherapy schedule predicts RP, although the studies were limited by varied drug regimens and schedules. Similar results were obtained from this study. The percentage of patients who developed RP in our study was higher in patients with combined chemoradiation compared with RT alone (41.7% vs. 16.7%, respectively), but this difference did not reach statistical significance (p=0.108), perhaps due to small sample size.

We noted that MLD and V₃₀ significantly predicted RP. In our studies, all RP grades were associated with dosimetric factors, such as MLD V₂₀, V₃₀, V40, and NTCP, similar to other reports [9-12], except in the cases of grade 5 fatal RP. The five patients with grade 5 RP in our study did not have worse dosimetric parameters than those with non-fatal RP. RP is usually limited to the irradiation field; however, in grade 5 RP patients of our study, their chest CT scans were characterized by diffuse interstitial infiltration and consolidation even outside the radiation field in the absence of an identifiable infectious organism. This suggests that other biologic factors might have contributed to RP deaths.

We analyzed the pre-RT chest CT scans of the RP patients and frequently observed diffuse honeycombing and diffuse nodular density patterns in high grade RP. Patients whose pre-RT chest CT scans revealed diffuse interstitial changes in either the entirety of both lungs or both lower lung fields had a greater risk of high grade RP. These patients must be carefully watched during chemoradiation and closely monitored following RT due to the increased risk. This is the essential point: the physician must monitor carefully even patients who are within the acceptable range results for the pulmonary function test prior to RT, even those with no history of symptomatic ILDs. Several Japanese studies have suggested that subclinical ILD found in CT scans before thoracic RT is related to fatal RP, and those patients have to be carefully evaluated [16,17,20]. Our study found that patients with interstitial lung change in CT have a significantly higher risk of severe RP, and that the interstitial change is a statistically significant prognostic factor for severe RP. Yamaguchi et al. [16] suggested that extensive interstitial change in pre-RT CT is a contraindication for thoracic RT. In our study, we obtained similar results. In addition we showed that five patients with grade 5 RP did not have higher dosimetric parameters compared to the non-fatal RP patients. Even if patients have reasonable dosimetric results in their radiotherapy planning, it is necessary to carefully evaluate and follow up with the patient due to their high risk of severe RP.

Several studies suggest that certain biological or physiological responses to radiation could explain RP and that these are not well predicted by the empiric dose-volume relationship. Further research that takes into consideration biologic markers may be necessary [21]. Tumor growth factor β1, interleukins 1, 6, 8, and 10, Krebs von den Lungen-6 (KL-6) and surfactant proteins (SP) are important biologic markers in the development of symptomatic radiation-induced lung injury. Interstitial change on the CT and high levels of biologic markers (KL-6, SP-D) were associated with an increased risk of severe RP [22]. Further study with a higher number of patients and several biologic factors is necessary to determine the relationships of interstitial change in pre-RT CT, biologic markers, and severe RP. It is hoped that further research will identify biomarkers that will allow us to tailor our treatment for lung cancer patients to avoid the development of severe RP.

There are several limitations in this study. As a retrospective study, this study has the possibility of selection bias. A small number of patients with short inclusion were analyzed in this study, because we explored this study as the extension of another study for RP. Patient characteristics and radiation treatment were heterogeneous. A prospective study with a larger number of patients will improve the result of this study. Despite these limitations, our findings are helpful to identify and follow the high risk patients of severe RP.

Conclusion

Our study identified diffuse interstitial disease as a significant clinical factor for the occurrence of RP and also showed the usefulness of dosimetric factors such as MLD, V₂₀, V₃₀, and NTCP in predicting the incidence and severity of RP. Four of our five grade 5 RP patients had interstitial changes in their pre-RT chest CTs. When image findings were analyzed in RP patients, diffuse honeycombing and diffuse nodular patterns were frequently observed in high grade RP. The patients with interstitial change in pre-RT CT have to be carefully evaluated and managed for severe RP after thoracic RT.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

The authors would like to acknowledge the statistical assistance of Catholic Medical Center Clinical Research Coordinating Center.

Fig. 1.

Cumulative curves of the development of RP, which were stratified by MLD (A), V₂₀ (B), V₃₀ (C), and NTCP (D). There were consistencies in that the higher RP rates were associated with higher MLD, V₂₀, V₃₀, and NTCP. Maintaining a MLD less than 15 Gy, V₂₀ < 25%, and V₃₀ < 20% could reduce the incidence of RP. RP, radiation pneumonitis; MLD, mean lung dose; V₂₀ and V₃₀, percent lung volume receiving more than 20 Gy and 30 Gy; NTCP, normal tissue complication probability.

Fig. 2.

The distribution of RP grade stratified by MLD (A), V₂₀ (B), V₃₀ (C), and NTCP (D). A MLD, V₂₀, V₃₀, V₄₀, and NTCP also were strongly associated with RP grade. However, all dosimetric parameters were even lower in grade 5 fatal RP. RP, radiation pneumonitis; MLD, mean lung dose; V₂₀ and V₃₀, percent lung volume receiving more than 20 Gy and 30 Gy; NTCP, normal tissue complication probability.

Fig. 3.

Representative of grade 5 fatal radiation pneumonitis patient. This patient was a 65 year-old male with non-small cell lung cancer, T2N2M0 (2.2-cm-sized fluorodeoxyglucose avid mass in right lower lobe (arrow) with metastatic lymphadenopathies in right interlobar and subcarina/right paraesophageal area) (A) treated with weekly docetaxel (20 mg/m²)+cisplatin (20 mg/m²) concurrent chemoradiotherapy (CCRT). Although, he had a history of interstitial lung disease diagnosed 2 years ago, he was in a clinically stable condition with acceptable pulmonary function (forced expiratory volume in 1 second, 2.2 L; carbon monoxide lung diffusion capacity, 74%). Initial chest computed tomography showed diffuse involvement of reticular opacity, subpleural ground glass opacity (arrows) (B), traction bronchiectasis (arrow) (C), and honeycombing (arrow) (D). One month after completing CCRT (59.4 Gy/33 fractions) (E), he achieved excellent partial response. The malignant tumor in right upper lobe showed partial metabolic response (arrow) (F) and minimal haziness was noted in the computed tomography (arrow) (G). However, he developed coughing, progressive dyspnea, and fever with newly developed diffuse interstitial infiltration and consolidation extending beyond radiation field 3 months after completion of radiation therapy (H, I). No specific infectious cause was identified. He died despite 2 weeks of intensive care.

Table 1.

Patient characteristics (n=60)

Characteristic		No. (%)
Median age (range, yr)		62 (40-80)
Gender (male:female)		48:12
ECOG PS	0	4 (6.7)
	1	33 (55.0)
	2	15 (25.0)
	3	8 (13.3)
Smoking	Yes	46 (76.7)
	No	12 (20.0)
	Unknown	2 (3.3)
Weight loss	Yes	21 (35.0)
Weight loss	No	39 (65.0)
COPD	Yes	24 (40.0)
COPD	No	36 (60.0)
Interstitial change in CT	Yes	15 (25.0)
Interstitial change in CT	No	45 (75.0)
Histology	NSCLC	39 (65.0)
	SCLC	18 (30.0)
	Other	3 (5.0)
Stage of NSCLC	I	1 (1.7)
	II	2 (3.3)
	III	33 (55.0)
	IV	3 (5.0)
Tumor location	Central	53 (88.3)
	Periphery	7 (11.7)
	Upper	39 (65.0)
	Lower	21 (35.0)
Surgery	Yes	14 (23.3)
Surgery	No	46 (76.7)
Chemotherapy	Yes	48 (80.0)
	No	12 (20.0)
	Sequential	27 (45.0)
	Concurrent	21 (35.0)

ECOG PS, Eastern Cooperative Oncology Group performance status; COPD, chronic obstructive pulmonary disease; CT, computed tomography; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

Table 2.

Association between clinical factors and RP by univariable analysis

Variable		No. of RPs/Total (%)	p-value^a)
Gender	Male	19/48 (39.6)	0.507
Gender	Female	3/12 (25.0)
ECOG PS	0	2/4 (50)	0.476
	1	13/33 (39.4)
	2	6/15 (40.0)
	3	1/8 (12.5)
Smoking	Yes	19/46 (41.3)	0.300
Smoking	No	3/12 (25.0)
Weight loss	Yes	7/21 (33.3)	0.783
Weight loss	No	15/39 (38.5)
COPD	Yes	8/24 (33.3)	0.662
COPD	No	14/36 (38.9)
Interstitial change in CT	Yes	9/15 (60.0)	0.033
Interstitial change in CT	No	13/45 (28.9)
Histology	NSCLC	14/39 (35.9)	0.969
Histology	SCLC	7/18 (38.9)
Stage	I	0/1 (0)	0.757
	II	1/2 (50)
	III	13/33 (39.4)
	IV	0/3 (0)
Tumor location	Central	20/53 (37.7)	0.636
	Periphery	2/7 (28.6)
	Upper	13/39 (33.3)	0.465
	Lower	9/21 (42.9)
Surgery	Yes	5/14 (35.7)	0.933
Surgery	No	17/46 (37.0)
Chemotherapy	Yes	20/48 (41.7)	0.108
	No	2/12 (16.7)
	Sequential	12/27 (44.4)	0.425
	Concurrent	8/21 (38.1)

RP, radiation pneumonitis; ECOG PS, Eastern Cooperative Oncology Group performance status; COPD, chronic obstructive pulmonary disease; CT, computed tomography; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

^a) Chi-squared test.

Table 3.

Association between dosimetric factors and RP by univariable analysis

Variable	Without RP	With RP	p-value^a)
Mean lung dose	1,452±419	1,996±407	< 0.001
V₁₀	35.2±10.2	48.5±13.8	< 0.001
V₂₀	24.2±7.4	37.0±11.8	< 0.001
V₃₀	18.7±7.5	28.9±7.1	< 0.001
V₄₀	11.9±6.5	18.9±4.6	< 0.001
NTCP	7.7±16.0	28.9±24.6	0.001

Values are presented as mean±standard deviation. RP, radiation pneumonitis; V₁₀, V₂₀, V₃₀, and V₄₀, percent lung volume receiving more than 10 Gy, 20 Gy, 30 Gy, and 40 Gy; NTCP, normal tissue complication probability.

^a) Student’s t test.

Table 4.

Risk of RP by interstitial lung disease in pre-RT CT

Pre-RT CT finding	All patients	RP Gr ≥ 1	RP Gr ≥ 2	RP Gr ≥ 3	RP Gr ≥ 4
Interstitial change in CT	15	9 (60)	7 (46.7)	6 (40)	5 (33.3)
No interstitial change in CT	45	13 (28.9)	7 (15.6)	2 (4.4)	2 (4.4)
p-value^a)		0.03	0.03	0.002	0.008

Values are presented as number (%). RP, radiation pneumonitis; RT, radiotherapy; CT, computed tomography; Gr, grade.

^a) p-values from group comparisons by chi-squared test and Fisher exact test.

Table 5.

Characteristic findings in pre-RT chest computed tomography of 22 patients with RP

No.	Age (yr)/Gender	Diagnosis	RT dose (Gy)	Treatment modality	RP grade	Interstitial change pattern	Involvement of interstitial change
1	56/M	NSCLC (T3N1M0)	59.4	Chemo-RT	4	Diffuse nodular density/focal reticular opacity	Entire lung
2	62/M	SCLC (LD)	55.8	RT alone	1	None	-
3	56/F	NSCLC (T4N3M0)	59.4	RT alone	2	None	-
4	57/M	NSCLC (T4N3M0)	59.4	Chemo-RT	1	Diffuse honeycombing/focal reticular, TB	Entire lung
5	65/M	SCLC (LD)	55.8	CCRT	2	Focal GGO/reticulat opacity	Both lower lobe
6	55/M	NSCLC (T3N0M0)	45.0	CCRT	5	Diffuse honeycombing	Entire lung
7	67/M	NSCLC (T2N3M0)	57.6	Chemo-RT	1	Diffuse nodular density/focal GGO	Both lower lobe
8	66/M	SCLC (LD)	50.4	CCRT	2	None	-
9	60/M	NSCLC (T4N2M0)	64.8	RT alone	1	None	-
10	64/M	SCLC (LD)	59.4	RT alone	1	None	-
11	53/M	SCLC (LD)	50.4	CCRT	1	None	-
12	51/M	SCLC (LD)	55.8	CCRT	2	None	-
13	65/M	NSCLC (T2N2M0)	59.4	CCRT	5	Diffuse honeycombing/focal TB/focal GGO	Entire lung
14	60/M	NSCLC (T3N2M0)	56.1	Chemo-RT	5	Diffuse nodular/TB	Both upper lobe
15	69/M	NSCLC (T3N2M0)	59.4	Chemo-RT	1	None	-
16	75/F	NSCLC (T4N0M0)	59.4	RT alone	2	None	-
17	63/M	SCLC (LD)	50.4	RT alone	1	None	-
18	57/M	NSCLC (T2N2M0)	59.4	CCRT	3	Diffuse honeycombing/reticular opacity	Entire lung
19	68/M	NSCLC (T4N2M0)	55.6	Chemo-RT	5	Diffuse honeycombing/TB	Entire lung
20	61/M	NSCLC (T2N3M0)	59.4	RT alone	2	None	-
21	72/F	NSCLC (T1N2M0)	64.8	RT alone	5	None	-
22	54/M	NSCLC (T4N3M0)	54.0	CCRT	4	None	-

RT, radiation therapy; RP, radiation pneumonitis; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; Chemo-RT, chemotherapy followed by radiation therapy; LD, limited disease; TB, traction bronchiectasis; CCRT, concurrent chemoradiotherapy; GGO, ground glass opacity.

Table 6.

Characteristics of the five patients with grade 5 RP

Age (yr)/Gender	Diagnosis (stage)	COPD	Pre-RT CT finding	Treatment modality	Chemotherapy regimen	RT dose (Gy)	MLD (Gy)	V₂₀ (%)	V₃₀ (%)	RP onset (mo)	Death (mo)
55/M	NSCLC (T3N0M0)	No	Diffuse honeycombing	CCRT	Cisplatin	45	15.22	29.48	24.82	0	3
65/M	NSCLC (T2N2M0)	No	Diffuse honeycombing/focal TB/focal GGO	CCRT	Docetaxel+cisplatin	59.4	26.73	57.67	42.56	1	3
60/M	NSCLC (T3N2M0)	Yes	Diffuse nodular/TB	Chemo-RT	Cisplatin+gemcitabine	56.1	22.22	46.02	27.53	0	1
68/M	NSCLC (T4N2M0)	No	Diffuse honeycombing/TB	Chemo-RT	Cisplatin+gemcitabine	55.6	19.12	34.57	27.1	1	1
72/F	NSCLC (T1N2M0)	Yes	None	RT alone	None	64.8	18.54	29.47	26.17	1.5	1.5

RP, radiation pneumonitis; COPD, chronic obstructive pulmonary disease; RT, radiation therapy; CT, computed tomography; MLD, mean lung dose; V₂₀ and V₃₀, percent lung volume receiving more than 20 Gy and 30 Gy; NSCLC, non-small cell lung cancer; CCRT, concurrent chemoradiotherapy; TB, traction bronchiectasis; GGO, ground glass opacity; Chemo-RT, chemotherapy followed by radiation therapy.

REFERENCES

1. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 1998;16:3316–22. Article PubMed
2. Toschi L, Cappuzzo F, Janne PA. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. Ann Oncol. 2007;18 Suppl 9:ix150–5. Article
3. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24. Article PubMed
4. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543–52. Article PubMed
5. Morgan GW, Breit SN. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys. 1995;31:361–9. Article PubMed
6. McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys. 1995;31:1187–203. Article PubMed
7. Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012;51:975–83. Article PubMed PMC
8. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85:444–50. Article PubMed PMC
9. Jin H, Tucker SL, Liu HH, Wei X, Yom SS, Wang S, et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol. 2009;91:427–32. Article PubMed PMC
10. Baker R, Han G, Sarangkasiri S, DeMarco M, Turke C, Stevens CW, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys. 2013;85:190–5. Article PubMed
11. Dang J, Li G, Ma L, Diao R, Zang S, Han C, et al. Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Acta Oncol. 2013;52:1175–80. Article PubMed
12. Park YH, Kim JS. Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer. Radiat Oncol J. 2013;31:34.Article PubMed PMC
13. Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, et al. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clin Lung Cancer. 2012;13:304–11. Article PubMed
14. Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5. Article PubMed
15. Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009;75:343–7. Article PubMed
16. Yamaguchi S, Ohguri T, Matsuki Y, Yahara K, Oki H, Imada H, et al. Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis. Int J Clin Oncol. 2015;20:45–52. Article PubMed
17. Sanuki N, Ono A, Komatsu E, Kamei N, Akamine S, Yamazaki T, et al. Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res. 2012;53:110–6. Article PubMed
18. Mueller-Mang C, Grosse C, Schmid K, Stiebellehner L, Bankier AA. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics. 2007;27:595–615. Article PubMed
19. Das SK, Zhou S, Zhang J, Yin FF, Dewhirst MW, Marks LB. Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. Int J Radiat Oncol Biol Phys. 2007;68:1212–21. Article PubMed PMC
20. Makimoto T, Tsuchiya S, Hayakawa K, Saitoh R, Mori M. Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol. 1999;29:192–7. Article PubMed
21. Graves PR, Siddiqui F, Anscher MS, Movsas B. Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol. 2010;20:201–7. Article PubMed
22. Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010;5:32.Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Association Between Lung Volume Reduction and Symptomatic Radiation Pneumonitis in Lung Cancer Patients Undergoing Definitive Concurrent Chemoradiotherapy
Jeong Won Lee, Sea-Won Lee, Hyeseon Kang, Yun Hee Lee
Clinical Lung Cancer.2026; 27(3): 98. CrossRef
From dosimetry to deep learning: personalized risk prediction models for radiation pneumonitis
Yi Zhou, Shiting Bai, Yajun Wu, Qian Li, Wei Song, Sisi Chen, Jianglin Chen, Jin Qian, Zhibing Wu, Bingqi Yu
Oncologie.2025; 27(5): 673. CrossRef
Radiation Pneumonitis Risk Assessment Using Fractal Analyses in NSCLC Patients Treated with Curative-Intent Radiotherapy
Jeongeun Hwang, Sun Myung Kim, Joon-Young Moon, Bona Lee, Jeongmin Song, Sookyung Lee, Hakyoung Kim
Life.2025; 15(10): 1596. CrossRef
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, K. Chouahnia, J. Behr, P.-Y. Brillet, H. Nunes
Revue des Maladies Respiratoires Actualités.2025; 17(2): 2S350. CrossRef
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)
Paolo Borghetti, Rolando D’Angelillo, Giorgio Facheris, Andrea Borghesi, Alessio Bruni, Paolo Ceruti, Katia Ferrari, Andrea Riccardo Filippi, Sara Ramella, Diego Signorelli, Giovanni Pappagallo, Umberto Ricardi, Serena Badellino, Elisabetta Balestro, Mart
Lung Cancer.2025; 210: 108807. CrossRef
Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia
Shuri Aoki, Hitoshi Ishikawa, Mio Nakajima, Naoyoshi Yamamoto, Shinichiro Mori, Tokuhiko Omatsu, Yuji Tada, Teruaki Mizobuchi, Satoshi Ikeda, Ichiro Yoshino, Shigeru Yamada
Cancers.2024; 16(3): 562. CrossRef
Research Progress of Idiopathic Pulmonary Fibrosis Complicated with Lung Cancer
Hao Ruan, Zihui Zhang, Jiao Tian, Mingjiang Li, Ting Xiao
International Journal of Cancer Management.2024;[Epub] CrossRef
Drug change from nintedanib to pirfenidone for the perioperative management of lung cancer with idiopathic pulmonary fibrosis: A case report
Yukiko Matsui, Mitsuhiro Abe, Yasufumi Uematsu, Yuki Onozato, Takayoshi Yamamoto, Takekazu Iwata
The Journal of the Japanese Association for Chest Surgery.2024; 38(5): 446. CrossRef
Preliminary Results of Developing Imaging Complexity Biomarkers for the Incidence of Severe Radiation Pneumonitis Following Radiotherapy in Non-Small Cell Lung Cancer Patients with Underlying Idiopathic Pulmonary Fibrosis
Jeongeun Hwang, Hakyoung Kim, Sun Myung Kim, Dae Sik Yang
Life.2024; 14(7): 897. CrossRef
CT-based different regions of interest radiomics analysis for acute radiation pneumonitis in patients with locally advanced NSCLC after chemoradiotherapy
Liqiao Hou, Kuifei Chen, Chao Zhou, Xingni Tang, Changhui Yu, Haijian Jia, Qianyi Xu, Suna Zhou, Haihua Yang
Clinical and Translational Radiation Oncology.2024; 48: 100828. CrossRef
Computed tomography patterns and clinical outcomes of radiation pneumonitis in non–small-cell lung cancer patients
Ji Hoon Choi, Hee Kang, Ji Su Lim, Ki-Nam Lee
Acta Radiologica Open.2024;[Epub] CrossRef
Populations particulières : impact de l’état général et des principales comorbidités et de leurs traitements sur la prise en charge thérapeutique locale des patients présentant un Cancer Bronchique Non à Petites Cellules
V. Gounant, R. Ezzedine, B. Duchemann, T. Pierret, S. Brosseau, Y. Castier, G. Zalcman, P. Mordant
Revue des Maladies Respiratoires Actualités.2024; 16(2): 2S290. CrossRef
Development of Imaging Complexity Biomarkers for Prediction of Symptomatic Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer, Focusing on Underlying Lung Disease
Jeongeun Hwang, Hakyoung Kim, Joon-Young Moon, Sun Myung Kim, Dae Sik Yang
Life.2024; 14(11): 1497. CrossRef
Longitudinal microcomputed tomography detects onset and progression of pulmonary fibrosis in conditional Nedd4-2 deficient mice
Dominik H. W. Leitz, Philip Konietzke, Willi L. Wagner, Mara Mertiny, Claudia Benke, Thomas Schneider, Rory E. Morty, Christian Dullin, Wolfram Stiller, Hans-Ulrich Kauczor, Marcus A. Mall, Julia Duerr, Mark O. Wielpütz
American Journal of Physiology-Lung Cellular and Molecular Physiology.2024; 327(6): L917. CrossRef
Hydroalcoholic Sumac Extract as a Protective Agent Against X-Ray-Induced Pulmonary Fibrosis
Faezeh Rezaie, Aboulfazl Ghafouri Khosroshahi, Amir Larki-Harchegani, Alireza Nourian, Hossein Khosravi
Reports of Biochemistry and Molecular Biology.2024; 13(2): 231. CrossRef
Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients
J. Pluvy, A. Zaccariotto, P. Habert, J. Bermudez, A. Mogenet, J.Y. Gaubert, P. Tomasini, L. Padovani, L. Greillier
Respiratory Medicine and Research.2023; 83: 100984. CrossRef
Predictors of high-grade radiation pneumonitis following radiochemotherapy for locally advanced non-small cell lung cancer: analysis of clinical, radiographic and radiotherapy-related factors
Elisabeth Weiss, Anthony Ricco, Nitai Mukhopadhyay, Leila Rezai Gharai, Xiaoyan Deng, Nuzhat Jan, Christopher Guy
Journal of Radiotherapy in Practice.2023;[Epub] CrossRef
Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease
Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Kei Nagasaki, Yoshifumi Sugawara, Toshiyuki Kozuki
Radiotherapy and Oncology.2023; 183: 109636. CrossRef
Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging
Nika Guberina, Florian Wirsdörfer, Martin Stuschke, Verena Jendrossek
Neoplasia.2023; 39: 100892. CrossRef
Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease
Maria Azhar, Rodeo Abrencillo, Saumil Gandhi, Mehmet Altan, Ajay Sheshadri
Current Opinion in Pulmonary Medicine.2023; 29(4): 248. CrossRef
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouanhia, P.Y. Brillet, H. Nunes
Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S214. CrossRef
Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease
Hakyoung Kim, Jeongeun Hwang, Sun Myung Kim, Juwhan Choi, Dae Sik Yang
BMC Cancer.2023;[Epub] CrossRef
Quantification of diffuse parenchymal lung disease in non‐small cell lung cancer patients with definitive concurrent chemoradiation therapy for predicting radiation pneumonitis
Ye Chan An, Jong Hoon Kim, Jae Myung Noh, Kyungmi Yang, You Jin Oh, Sung Goo Park, Hong Ryul Pyo, Ho Yun Lee
Thoracic Cancer.2023; 14(36): 3530. CrossRef
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata
Radiation Oncology.2022;[Epub] CrossRef
Palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective
Satoshi Ikeda
Radiotherapy and Oncology.2022; 169: 155. CrossRef
Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review
A. Saha, P. Dickinson, R.K. Shrimali, A. Salem, S. Agarwal
Clinical Oncology.2022; 34(12): e493. CrossRef
Prospective Study of Proton Therapy for Lung Cancer Patients with Poor Lung Function or Pulmonary Fibrosis
Jae Myoung Noh, Hongseok Yoo, Woojin Lee, Hye Yun Park, Sun Hye Shin, Hongryull Pyo
Cancers.2022; 14(6): 1445. CrossRef
Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia
Shingo Hashimoto, Hiromitsu Iwata, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Eiko Yamamori, Kenji Akita, Jun-etsu Mizoe, Hiroyuki Ogino, Yuta Shibamoto
Radiation Oncology.2022;[Epub] CrossRef
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
B. Duchemann, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouahnia, P.-Y. Brillet, H. Nunes
Revue des Maladies Respiratoires Actualités.2022; 14(2): 2S378. CrossRef
Quantitative Assessment and Comparative Analysis of Longitudinal Lung CT Scans of Chest-Irradiated Nonhuman Primates
Priyanka Thakur, John D. Olson, Gregory O Dugan, J. Daniel Bourland, Nancy D. Kock, J. Mark Cline
Radiation Research.2022;[Epub] CrossRef
An Evaluation of Potent Radioprotective Effect of Dimethyl Sulfoxide for Acute Radiation-Induced Lung Injury: Tc99m-DTPA Transalveolar Clearance Scintigraphy Correlated by Histopathologic Findings
Bengu DEPBOYLU
Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi.2022; 9(3): 266. CrossRef
Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Yuichiro Ohe, Masahiko Kusumoto, Jun Itami
Advances in Radiation Oncology.2021; 6(1): 100606. CrossRef
Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
Görkem Türkkan, Yves Willems, Lizza E.L. Hendriks, Rémy Mostard, Lennart Conemans, Hester A Gietema, Cristina Mitea, Stéphanie Peeters, Dirk De Ruysscher
Radiotherapy and Oncology.2021; 155: 269. CrossRef
Radiation-induced lung injury: current evidence
Marisol Arroyo-Hernández, Federico Maldonado, Francisco Lozano-Ruiz, Wendy Muñoz-Montaño, Mónica Nuñez-Baez, Oscar Arrieta
BMC Pulmonary Medicine.2021;[Epub] CrossRef
Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy
Annemarie F. Shepherd, Michelle Iocolano, Jonathan Leeman, Brandon S. Imber, Aaron T. Wild, Michael Offin, Jamie E. Chaft, James Huang, Andreas Rimner, Abraham J. Wu, Daphna Y. Gelblum, Narek Shaverdian, Charles B. Simone, Daniel R. Gomez, Ellen D. Yorke,
Practical Radiation Oncology.2021; 11(1): e52. CrossRef
Scarred Lung. An Update on Radiation-Induced Pulmonary Fibrosis
Natalia Jarzebska, Ekaterina S. Karetnikova, Alexander G. Markov, Michael Kasper, Roman N. Rodionov, Peter M. Spieth
Frontiers in Medicine.2021;[Epub] CrossRef
Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
Ho Cheol Kim, Seonjeong Lee, Jin Woo Song
Scientific Reports.2021;[Epub] CrossRef
Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy
Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu
Radiation Oncology.2021;[Epub] CrossRef
Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease
Masayuki Okumura, Hidehiro Hojo, Masaki Nakamura, Takashi Hiyama, Naoki Nakamura, Sadamoto Zenda, Atsushi Motegi, Yasuhiro Hirano, Shun-Ichiro Kageyama, Raturi Vijay Parshuram, Takeshi Fujisawa, Hirofumi Kuno, Tetsuo Akimoto
Radiotherapy and Oncology.2021; 161: 47. CrossRef
Clinical Outcomes of Pencil Beam Scanning Proton Therapy in Locally Advanced Non-Small Cell Lung Cancer: Propensity Score Analysis
Nalee Kim, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hongryull Pyo
Cancers.2021; 13(14): 3497. CrossRef
Survival analysis in lung cancer patients with interstitial lung disease
Hassan Alomaish, Yee Ung, Stella Wang, Pascal N. Tyrrell, Saly Abo Zahra, Anastasia Oikonomou, Claudia Staab-Weijnitz
PLOS ONE.2021; 16(9): e0255375. CrossRef
Fatal Radiation Pneumonitis: Literature Review and Case Series
Stephen Keffer, Christopher L. Guy, Elisabeth Weiss
Advances in Radiation Oncology.2020; 5(2): 238. CrossRef
Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease
Yasuhito Hagiwara, Yuko Nakayama, Shigehiro Kudo, Toyokazu Hayakawa, Naoki Nakamura, Yoshizumi Kitamoto, Shigeo Takahashi, Kayoko Tsujino, Nobuteru Kubo, Yukihisa Tamaki, Yasushi Nagata
Journal of Radiation Research.2020; 61(4): 563. CrossRef
Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
Minjiang Chen, Xiaoyan Liu, Yan Xu, Qing Zhou, Yuequan Shi, Dongming Zhang, Hongge Liang, Jing Zhao, Wei Zhong, Mengzhao Wang
The Clinical Respiratory Journal.2020; 14(12): 1131. CrossRef
Stereotactic Body Radiation Therapy versus Thermal Ablation for Early Stage Non–Small Cell Lung Cancer
Melissa A. L. Vyfhuis, Pranshu Mohindra, Charles B. Simone
Radiology.2019; 290(2): 574. CrossRef
Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy
Hakyoung Kim, Hongryull Pyo, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hye Yun Park, Hongseok Yoo
Radiation Oncology.2019;[Epub] CrossRef
Neutrophil‐lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non‐small‐cell lung cancer patients treated with concurrent chemoradiotherapy
Yun Hee Lee, Hoon‐Sik Choi, Hojin Jeong, Ki Mun Kang, Jin Ho Song, Won Sup Lee, Gyeong‐Won Lee, Haa‐Na Song, Hoon‐Gu Kim, Myoung Hee Kang, Dong Yoon Rhee, Bae Kwon Jeong
The Clinical Respiratory Journal.2018; 12(3): 1264. CrossRef
Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
Daniel Glick, Stephen Lyen, Sonja Kandel, Shane Shapera, Lisa W. Le, Patricia Lindsay, Olive Wong, Andrea Bezjak, Anthony Brade, B.C. John Cho, Andrew Hope, Alexander Sun, Meredith Giuliani
Clinical Lung Cancer.2018; 19(2): e219. CrossRef
The Association Between the Serum KL-6 Level and the Risk of Radiation Pneumonitis
Minehiko Inomata, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toru Yamada, Toshiro Miwa, Kentaro Yamagishi, Kuninori Nomura, Ryuji Hayashi, Kazuyuki Tobe
Haigan.2018; 58(1): 19. CrossRef
Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function
Takeaki Ishihara, Kazunari Yamada, Aya Harada, Haruhiro Yukiue, Masayuki Tanahashi, Hiroshi Niwa, Takashi Matsui, Koshi Yokomura, Yasuo Ejima, Ryohei Sasaki
Acta Oncologica.2018; 57(9): 1232. CrossRef
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona-Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson
Clinical Lung Cancer.2018; 19(6): e893. CrossRef
Managing the oncologic patient with suspected pneumonia in the intensive care unit
D. Leoni, B. Encina, J. Rello
Expert Review of Anti-infective Therapy.2016; 14(10): 943. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis

Cancer Res Treat. 2015;47(4):676-686. Published online February 13, 2015

DOI: https://doi.org/10.4143/crt.2014.180

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis

Fig. 1. Cumulative curves of the development of RP, which were stratified by MLD (A), V20 (B), V30 (C), and NTCP (D). There were consistencies in that the higher RP rates were associated with higher MLD, V20, V30, and NTCP. Maintaining a MLD less than 15 Gy, V20 < 25%, and V30 < 20% could reduce the incidence of RP. RP, radiation pneumonitis; MLD, mean lung dose; V20 and V30, percent lung volume receiving more than 20 Gy and 30 Gy; NTCP, normal tissue complication probability.

Fig. 2. The distribution of RP grade stratified by MLD (A), V20 (B), V30 (C), and NTCP (D). A MLD, V20, V30, V40, and NTCP also were strongly associated with RP grade. However, all dosimetric parameters were even lower in grade 5 fatal RP. RP, radiation pneumonitis; MLD, mean lung dose; V20 and V30, percent lung volume receiving more than 20 Gy and 30 Gy; NTCP, normal tissue complication probability.

Fig. 3. Representative of grade 5 fatal radiation pneumonitis patient. This patient was a 65 year-old male with non-small cell lung cancer, T2N2M0 (2.2-cm-sized fluorodeoxyglucose avid mass in right lower lobe (arrow) with metastatic lymphadenopathies in right interlobar and subcarina/right paraesophageal area) (A) treated with weekly docetaxel (20 mg/m2)+cisplatin (20 mg/m2) concurrent chemoradiotherapy (CCRT). Although, he had a history of interstitial lung disease diagnosed 2 years ago, he was in a clinically stable condition with acceptable pulmonary function (forced expiratory volume in 1 second, 2.2 L; carbon monoxide lung diffusion capacity, 74%). Initial chest computed tomography showed diffuse involvement of reticular opacity, subpleural ground glass opacity (arrows) (B), traction bronchiectasis (arrow) (C), and honeycombing (arrow) (D). One month after completing CCRT (59.4 Gy/33 fractions) (E), he achieved excellent partial response. The malignant tumor in right upper lobe showed partial metabolic response (arrow) (F) and minimal haziness was noted in the computed tomography (arrow) (G). However, he developed coughing, progressive dyspnea, and fever with newly developed diffuse interstitial infiltration and consolidation extending beyond radiation field 3 months after completion of radiation therapy (H, I). No specific infectious cause was identified. He died despite 2 weeks of intensive care.

Fig. 1.

Fig. 2.

Fig. 3.

Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis

Characteristic		No. (%)
Median age (range, yr)		62 (40-80)
Gender (male:female)		48:12
ECOG PS	0	4 (6.7)
	1	33 (55.0)
	2	15 (25.0)
	3	8 (13.3)
Smoking	Yes	46 (76.7)
	No	12 (20.0)
	Unknown	2 (3.3)
Weight loss	Yes	21 (35.0)
Weight loss	No	39 (65.0)
COPD	Yes	24 (40.0)
COPD	No	36 (60.0)
Interstitial change in CT	Yes	15 (25.0)
Interstitial change in CT	No	45 (75.0)
Histology	NSCLC	39 (65.0)
	SCLC	18 (30.0)
	Other	3 (5.0)
Stage of NSCLC	I	1 (1.7)
	II	2 (3.3)
	III	33 (55.0)
	IV	3 (5.0)
Tumor location	Central	53 (88.3)
	Periphery	7 (11.7)
	Upper	39 (65.0)
	Lower	21 (35.0)
Surgery	Yes	14 (23.3)
Surgery	No	46 (76.7)
Chemotherapy	Yes	48 (80.0)
	No	12 (20.0)
	Sequential	27 (45.0)
	Concurrent	21 (35.0)

Variable		No. of RPs/Total (%)	p-value^a)
Gender	Male	19/48 (39.6)	0.507
Gender	Female	3/12 (25.0)
ECOG PS	0	2/4 (50)	0.476
	1	13/33 (39.4)
	2	6/15 (40.0)
	3	1/8 (12.5)
Smoking	Yes	19/46 (41.3)	0.300
Smoking	No	3/12 (25.0)
Weight loss	Yes	7/21 (33.3)	0.783
Weight loss	No	15/39 (38.5)
COPD	Yes	8/24 (33.3)	0.662
COPD	No	14/36 (38.9)
Interstitial change in CT	Yes	9/15 (60.0)	0.033
Interstitial change in CT	No	13/45 (28.9)
Histology	NSCLC	14/39 (35.9)	0.969
Histology	SCLC	7/18 (38.9)
Stage	I	0/1 (0)	0.757
	II	1/2 (50)
	III	13/33 (39.4)
	IV	0/3 (0)
Tumor location	Central	20/53 (37.7)	0.636
	Periphery	2/7 (28.6)
	Upper	13/39 (33.3)	0.465
	Lower	9/21 (42.9)
Surgery	Yes	5/14 (35.7)	0.933
Surgery	No	17/46 (37.0)
Chemotherapy	Yes	20/48 (41.7)	0.108
	No	2/12 (16.7)
	Sequential	12/27 (44.4)	0.425
	Concurrent	8/21 (38.1)

Variable	Without RP	With RP	p-value^a)
Mean lung dose	1,452±419	1,996±407	< 0.001
V₁₀	35.2±10.2	48.5±13.8	< 0.001
V₂₀	24.2±7.4	37.0±11.8	< 0.001
V₃₀	18.7±7.5	28.9±7.1	< 0.001
V₄₀	11.9±6.5	18.9±4.6	< 0.001
NTCP	7.7±16.0	28.9±24.6	0.001

Pre-RT CT finding	All patients	RP Gr ≥ 1	RP Gr ≥ 2	RP Gr ≥ 3	RP Gr ≥ 4
Interstitial change in CT	15	9 (60)	7 (46.7)	6 (40)	5 (33.3)
No interstitial change in CT	45	13 (28.9)	7 (15.6)	2 (4.4)	2 (4.4)
p-value^a)		0.03	0.03	0.002	0.008

No.	Age (yr)/Gender	Diagnosis	RT dose (Gy)	Treatment modality	RP grade	Interstitial change pattern	Involvement of interstitial change
1	56/M	NSCLC (T3N1M0)	59.4	Chemo-RT	4	Diffuse nodular density/focal reticular opacity	Entire lung
2	62/M	SCLC (LD)	55.8	RT alone	1	None	-
3	56/F	NSCLC (T4N3M0)	59.4	RT alone	2	None	-
4	57/M	NSCLC (T4N3M0)	59.4	Chemo-RT	1	Diffuse honeycombing/focal reticular, TB	Entire lung
5	65/M	SCLC (LD)	55.8	CCRT	2	Focal GGO/reticulat opacity	Both lower lobe
6	55/M	NSCLC (T3N0M0)	45.0	CCRT	5	Diffuse honeycombing	Entire lung
7	67/M	NSCLC (T2N3M0)	57.6	Chemo-RT	1	Diffuse nodular density/focal GGO	Both lower lobe
8	66/M	SCLC (LD)	50.4	CCRT	2	None	-
9	60/M	NSCLC (T4N2M0)	64.8	RT alone	1	None	-
10	64/M	SCLC (LD)	59.4	RT alone	1	None	-
11	53/M	SCLC (LD)	50.4	CCRT	1	None	-
12	51/M	SCLC (LD)	55.8	CCRT	2	None	-
13	65/M	NSCLC (T2N2M0)	59.4	CCRT	5	Diffuse honeycombing/focal TB/focal GGO	Entire lung
14	60/M	NSCLC (T3N2M0)	56.1	Chemo-RT	5	Diffuse nodular/TB	Both upper lobe
15	69/M	NSCLC (T3N2M0)	59.4	Chemo-RT	1	None	-
16	75/F	NSCLC (T4N0M0)	59.4	RT alone	2	None	-
17	63/M	SCLC (LD)	50.4	RT alone	1	None	-
18	57/M	NSCLC (T2N2M0)	59.4	CCRT	3	Diffuse honeycombing/reticular opacity	Entire lung
19	68/M	NSCLC (T4N2M0)	55.6	Chemo-RT	5	Diffuse honeycombing/TB	Entire lung
20	61/M	NSCLC (T2N3M0)	59.4	RT alone	2	None	-
21	72/F	NSCLC (T1N2M0)	64.8	RT alone	5	None	-
22	54/M	NSCLC (T4N3M0)	54.0	CCRT	4	None	-

Age (yr)/Gender	Diagnosis (stage)	COPD	Pre-RT CT finding	Treatment modality	Chemotherapy regimen	RT dose (Gy)	MLD (Gy)	V₂₀ (%)	V₃₀ (%)	RP onset (mo)	Death (mo)
55/M	NSCLC (T3N0M0)	No	Diffuse honeycombing	CCRT	Cisplatin	45	15.22	29.48	24.82	0	3
65/M	NSCLC (T2N2M0)	No	Diffuse honeycombing/focal TB/focal GGO	CCRT	Docetaxel+cisplatin	59.4	26.73	57.67	42.56	1	3
60/M	NSCLC (T3N2M0)	Yes	Diffuse nodular/TB	Chemo-RT	Cisplatin+gemcitabine	56.1	22.22	46.02	27.53	0	1
68/M	NSCLC (T4N2M0)	No	Diffuse honeycombing/TB	Chemo-RT	Cisplatin+gemcitabine	55.6	19.12	34.57	27.1	1	1
72/F	NSCLC (T1N2M0)	Yes	None	RT alone	None	64.8	18.54	29.47	26.17	1.5	1.5

Table 1. Patient characteristics (n=60)

ECOG PS, Eastern Cooperative Oncology Group performance status; COPD, chronic obstructive pulmonary disease; CT, computed tomography; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

Table 2. Association between clinical factors and RP by univariable analysis

Chi-squared test.

Table 3. Association between dosimetric factors and RP by univariable analysis

Student’s t test.

Table 4. Risk of RP by interstitial lung disease in pre-RT CT

Values are presented as number (%). RP, radiation pneumonitis; RT, radiotherapy; CT, computed tomography; Gr, grade.

p-values from group comparisons by chi-squared test and Fisher exact test.

Table 5. Characteristic findings in pre-RT chest computed tomography of 22 patients with RP